68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

This publication has 37 references indexed in Scilit:

• 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
  European Journal of Nuclear Medicine and Molecular Imaging, 2017
• Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries
  European Urology, 2016
• German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
  Journal of Nuclear Medicine, 2016
• PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
  Journal of Nuclear Medicine, 2016
• Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer
  Seminars in Nuclear Medicine, 2016
• Future trends in prostate cancer theranostics with PSMA ligands
  Clinical and Translational Imaging, 2016
• Response and Tolerability of a Single Dose of¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
  Journal of Nuclear Medicine, 2016
• Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
  Journal of Nuclear Medicine, 2015
• PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
  Theranostics, 2015
• Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
  Journal of Cellular Biochemistry, 2003